CEL-SCI to Present at Rodman & Renshaw 4th Annual Global Healthcare Conference

VIENNA, Va., May 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announced that Geert Kersten, Chief Executive Officer, will be presenting at the Rodman & Renshaw 4th Annual Global Healthcare Conference being held at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco from May 14-15, 2007. The presentation will be focused on its Phase III cancer product Multikine(R) which is the first biotech cancer product seeking to become a new first line standard of care treatment in cancer.

Mr. Kersten's presentation will be on Tuesday, May 15th, at 11:10 a.m. local time or 5:10 a.m. EDT. The presentation will be webcast live with slides and archived for 90 days after the conference. The webcast can be accessed at http://www.cel-sci.com.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has received the go-ahead from the U.S. FDA and the Canadian Regulators to conduct a Phase III clinical trial in advanced primary head and neck cancer patients with its lead product Multikine. CEL-SCI's other products, which are currently in pre-clinical stage and have been funded with U.S. government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases associated with bio-defense and avian flu. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460

Web site: http://www.cel-sci.com/